The extracellular matrix (ECM) is a three-dimensional, non-cellular structure that is present in all tissues and is essential for life. Every organ has an ECM with unique composition that is generated in early embryonic stages. The function of the ECM goes beyond providin g physical support for tissue integrity and elasticity: it is a dynamic structure that is constantly remodelled to control tissue homeostasis 1 . The functional importance of the ECM is illustrated by the wide range of tissu e defects or, in severe cases, the embryonic lethality caused by mutations in genes that encode components of the ECM 2, 3 . Loss-of-function studies have also shown the importance of ECM proteins in developmental processes, as genetic deletion of specific ECM proteins such as fibronectin and collagens are often embryonic lethal (reviewed in REF. 4).
The extracellular matrix (ECM) is a three-dimensional, non-cellular structure that is present in all tissues and is essential for life. Every organ has an ECM with unique composition that is generated in early embryonic stages. The function of the ECM goes beyond providin g physical support for tissue integrity and elasticity: it is a dynamic structure that is constantly remodelled to control tissue homeostasis 1 . The functional importance of the ECM is illustrated by the wide range of tissu e defects or, in severe cases, the embryonic lethality caused by mutations in genes that encode components of the ECM 2, 3 . Loss-of-function studies have also shown the importance of ECM proteins in developmental processes, as genetic deletion of specific ECM proteins such as fibronectin and collagens are often embryonic lethal (reviewed in REF. 4 ).
In mammals, the ECM is composed of around 300 proteins, known as the core matrisome, and includes proteins such as collagen, proteoglycans (PGs) and glycoproteins (reviewed in REF. 5 ). There are two main types of ECM that differ with regard to their location and composition: the interstitial connective tissue matrix, which surrounds cells and provides structural scaffolding for tissues; and the basement membrane, which is a specialized form of ECM that separates the epithelium from the surrounding stroma
.
Components of the ECM constantly interact with epithelial cells by serving as ligands for cell receptors such as integrins, thereby transmitting signals that regulate adhesion, migration, proliferation, apoptosis, survival or differentiation. The ECM can also sequester and locally release growth factors, such as epidermal growth factor (EGF), fibroblast growth factor (FGF) and other signalling molecules (such as WNTs, transforming growth factor-β (TGFβ) and amphiregulin). ECM components released through ECM cleavage also regulate ECM architecture and influence cell behaviour 1 . Moreover, cells are constantly rebuilding and remodelling the ECM through synthesis, degradation, reassembly and chemical modification 6 . These processes are complex and need to be tightly regulated to maintain tissue homeostasis, especially in response to injury. Indeed, dysregulated ECM remodelling is associated with pathological conditions and can exacerbate disease progression. For example, abnormal ECM deposition and stiffness are observed in fibrosis and cancer 7 , and excessive ECM degradation is linked to osteoarthritis 8 . Here, we review recent advances in our understanding of ECM dynamics in development and tissue homeo stasis and discuss how dysregulation of ECM structure and composition leads to disease. We first describe the endopeptidases that degrade and cleave ECM components, which can also generate fragments with biological functions that differ from their fulllength counterparts. We then summarize progress in elucidating the molecular mechanisms underlying the role of the ECM during normal morphogenesis, focusing on the best known examples: the development of the intestine, the lungs and the mammary and submandibula r glands (also known as salivary glands). Finally, we discuss how dysregulated ECM remodelling leads to diseases such as fibrosis and cancer and highlight some ECM-related targets with therapeutic potential that are currently being tested in clinical trials. These conceptual advances in understanding the ECM in physiological and pathological processes will guide us in developing better therapies for disease.
Meprins. The meprins belong to the astacin family and are composed of two subunits (α and β) that are encoded by two different genes 15 . The subunits can
Box 1 | The mammalian matrisome
Using different proteomic techniques and analysing the human and mouse genomes, Hynes and colleagues reported what is so far the most comprehensive list of proteins that define the matrisome in mammals. Among these, ~300 proteins constitute the core matrisome, which consists of 43 collagen subunits, 36 proteoglycans (PGs) and ~200 complex glycoproteins 5 . Collagens are the main structural proteins of the extracellular matrix (ECM) and are classified into both fibrillar (collagens I-III, V and XI) and non-fibrillar forms. Collagen fibrils provide tensile strength to the ECM, limiting the distensibility of tissues.
PGs, such as aggrecan, versican, perlecan and decorin, are core proteins with attached glycosaminoglycan (GAG) side chains and are interspersed among collagen fibrils. PGs fill the extracellular interstitial space and confer hydration functions by sequestering water within the tissue. GAGs, especially heparin sulphates, also bind many growth factors, which sequester them in the ECM.
Glycoproteins, such as laminins, elastin, fibronectins, thrombospondins, tenascins and nidogen, have diverse functions. In addition to their role in ECM assembly, they are also involved in ECM-cell interaction by acting as ligands for cell surface receptors such as integrins. Glycoproteins also function as a reservoir of growth factors, which are bound to the ECM and can be released after proteolysis. Cleavage of glycoproteins can generate fragments with different functions than in their original full-length protein.
In addition, there are many ECM-associated proteins that are not part of the matrisome but are nonetheless important in ECM remodelling. These proteins are growth factors and cytokines, mucins, secreted C-type lectins, galectins, semaphorins, plexins and ECM-modifying enzymes that are involved in crosslinking (for example, transglutaminase, lysyl oxidase and hydroxylase).
There are two main types of ECM: the interstitial connective tissue matrix and the basement membrane, a specialized form of ECM separating epithelium from the surrounding stroma and controlling cell organization and differentiation through interactions with cell surface receptors and ECM proteins (see the figure) . The interstitial matrix surrounds cells and is mainly composed of collagen I and fibronectin, which provide structural scaffolding for tissues. By contrast, the basement membrane is more compact than the interstitial matrix and mainly consists of collagen IV, laminins, heparan sulphate proteoglycans (HSPGs) and proteins, such as nidogen and entactin, that are synthesized and secreted by epithelial cells, endothelial cells and underlying integrin-expressing myofibroblasts 95 . Basement membrane express different receptors, such as integrins and hemidesmosomes, that bind to ECM proteins. Hemidesmosomes include two transmembrane proteins, α6β4 integrin and BP180 (180 kDa bullous pemphigoid antigen 2) and two cytoplasmic proteins, BP230 and plectin, that are related to the cytoskeleton. ECM proteins can bind other receptors such as dystroglycan, the Lutheran glycoprotein and sulphated glycolipids such as sulphatides 136 (see the figure). 
Zymogens
Proenzymes that are inactive enzyme precursors. Zymogens need to be biochemically modified to become active enzymes.
Integrins
Heterodimeric cell surface receptors that mediate cellcell and cell-ECM interactions and orchestrate cell attachment, movement, growth, differentiation and survival.
form heterocomplexes and homocomplexes linked by disulphide bridges 16 . In contrast to meprin-α (which is a secreted protein as it loses its transmembrane domain by cleavage during biosynthesis), meprin-β is predominantly expressed on the cell surface but can be released from the membrane by shedding via ADAM10 (REF. 17 ). Meprins can cleave ECM proteins such as collagen IV, nidogen and fibronectin 18 (FIG. 1) . In addition, meprins may be necessary for the generation of mature collagen molecules by cleaving pro-collagen I that is assembled into collagen fibrils, which are important for skin tensil e strength 19 . Meprins can also indirectly regulate ECM remodelling by activating the other metalloproteinases. For example, ADAM10 is cleaved by meprin-β 20 , and both meprin-α and meprin-β promote the cleavage of pro-MMP9 by MMP3, thus accelerating the activation of MMP9 (REF. 21 ). Compared with the other metalloproteinases, the roles of meprins in ECM remodelling are poorly understood.
Metalloproteinase inhibitors. ECM proteolysis requires tight regulation to avoid excessive and deleterious tissu e degradation. The activity of endogenous inhibitors that inactivate ECM proteinases is thus important for tissue integrity. The tissue inhibitor of metalloproteinases (TIMP) family consists of four members (TIMP1-TIMP4) that reversibly inhibit the activity of MMPs, ADAMs and ADAMTS, but not of meprins. MMP-to-TIMP ratios determine the overall proteolytic activity, and each TIMP displays preferential MMP-binding specificity (reviewed in REF. 22 ). TIMP3 is sequestered in the ECM, whereas the other TIMPs are present in soluble form in vivo. Although TIMP3 is the main inhibitor of ADAMs and ADAMTS, the membraneassociated RECK (reversion-inducing Cys-rich protein with Kazal motifs) also regulates the activity of MMPs and ADAMs 23 . Cystatin C, elafin and fetuin A have been identified as natural inhibitors of meprins 20 .
Other enzymes important in ECM remodelling. Ser proteases can also target many ECM proteins. The two plasminogen activators urokinase and tissue plasminogen activator target plasminogen to generate plasmin, a protein that degrades fibrin, fibronectin and laminin 24 . Moreover, the Ser protease elastase is released by neutrophils and promotes the breakdown of fibronectin and elastin 25 , and the membrane-anchored Ser protease matriptase, which is expressed by epithelial cells, is important in maintaining the intestinal barrier (reviewed in REF. 26 ).
In addition, cathepsins are found both extracellularly and intracellularly in lysosomes. Secreted cathepsins degrade extracellular ECM proteins, but many cells can also internalize ECM components such as collagen through endocytosis and degrade them in the lysosomes 27 29 .
ECM dynamics in intestinal development
In vertebrates, the intestine is formed from the embryonic endoderm layer, which undergoes multiple morphological changes to give rise to an adult epithelium with finger-like luminal projections called villi and epithelial invaginations called intestinal crypts. Within these crypts reside intestinal stem cells, which express Leu-rich-repeat-containing G protein-coupled receptor 5 (LGR5) 30 . To illustrate the roles of the ECM in development, we discuss our current understanding of how the ECM regulates intestinal morphogenesis in anura n (for example, frog and toad) tadpoles and in other vertebrates.
Intestinal morphogenesis in anurans. The anuran tadpole intestine is composed of a simple tubular organ made of a monolayer of epithelial cells (FIG. 2a) . Metamorphosis from tadpole to the adult anuran ◀ Figure 1 
Intestinal stem cells
Undifferentiated cells that can self-renew and differentiate into all of the specialized cell types of the tissue or organ. The main role of stem cells is to maintain and repair the tissue in which they reside.
RGD-dependent integrins
A group of integrins that specifically recognize the RGD motif, a sequence of three amino acids (Arg-Gly-Asp) found in many ECM molecules such as fibronectin and osteopontin. Collectively, these interactions are termed the RGD-dependent adhesion system.
Anoikis
A programmed cell death that is induced by lack of correct cell-ECM interactions. Invasive tumour cells may escape from anoikis to target different metastatic organs.
Organoids
Organ epithelial fragments that resemble the whole organ in structure and function during three-dimensional culture.
Stem cell niche
A specialized microenvironment that interacts with cells such as stem cells or tumour cells to regulate their fate.
involves the death of these cells, which undergo apoptosis induced by thyroid hormone; meanwhile, the adult epithelial cells proliferate rapidly (reviewed in REF. 31 ). During intestinal metamorphosis, the basement membrane also thickens, which suggests that the ECM might have a role in intestinal morphogenesis. Moreover, the addition of the ECM proteins laminin, collagen and fibronectin in vitro inhibits tadpole epithelial cell apoptosis induced by thyroid hormone 32 , which supports the idea that ECM remodelling influences cell fate during intestinal morphogenesis.
Several MMPs induced by thyroid hormone durin g metamorphosis have a pivotal role in remodelling the intestine. For example, MMP11 (also known as stromelysi n 3) is released and activated by fibroblasts after thyroid hormone stimulation 33 and is essential for epithelial cell apoptosis and invasion of the connective tissue during metamorphosis 34 (FIG. 2a) . Although the exact role of MMP11 is unknown, MMP11 can cleave laminin receptor and may therefore affect cell fate and migration during intestinal development 35 . Other MMPs, such as MMP2, MMP9 and MMP14 (also known as membrane type 1 MP; MT1MMP) 36 , are also upregulated during tadpole metamorphosis in response to thyroid hormone. The levels of MMP2 and MMP9 increase following epithelial cell death, suggesting that, in contrast to MMP11, these MMPs may have a role in post-apoptosis ECM remodelling at later stages of intestinal morphogenesis. Despite the fact that both of these MMPs function cooperatively during metamorphosis by contributing to the MMP14-mediated activation of pro-MMP2, their exact biological role in intestinal developmen t has not been elucidated 37 .
Intestinal morphogenesis in other vertebrates. In mammals, the involvement of ECM remodelling in intestinal development was first suggested by changes in the levels and localization of ECM proteins along the intestinal v illus-crypt axis (reviewed in REF. 38 ). For example, in the perinatal rat intestine, there is a transient disappearance of fibro nectin and pro-collagen III at the top of the outgrowing villus, whereas the basement membrane proteins are restricted to the base of the villi when crypts develop 39 . In addition, the levels of collagen IV mRNA synthesized by the mesenchyme are high during intestinal morphogenesis, suggesting an important role for this type of colla gen in gut development 40 .
Laminins also play an important part in cell-ECM interactions during intestinal morphogenesis and differentiation (reviewed in REF. 41 ). For example, mice lacking the laminin 511 α5 chain in the small intestina l basement membrane compensate by depositing colonic laminins (laminin 111 and laminin 411), which results in the transformation of the small intestine to a tissue with a colon-like mucosal architecture characterized by high levels of cell proliferation, probably owing to decreases levels of the cell cycle regulator cyclindependent kinase inhibitor B (CDKN1B) 42 
(FIG. 2b).
These studies show that ECM content remodelling has a crucial role in guiding tissue architecture during intestina l development.
Integrins are differentially expressed during intestinal development (reviewed in REF. 43 ). Interestingly, in vitro studies show that intestinal epithelial cells express RGD-dependent integrins, which recognize the RGD motif found in many ECM molecules, such as fibronectin, to anchor to the ECM and control their position and fate. In human intestinal epithelial crypt (HIEC) cells, which share features with intestinal epithelial stem cells, the interaction of α8β1 integrin with the ECM regulates adhesion, migration and cell proliferation via a ROCK (RHOassociated protein kinase)-dependent mechanism 44 . This serves as a checkpoint to regulate anoikis sensitivity, with adhesion preventing anoikis through the recruitment of vinculin and the activation of phosphoinositide 3-kinase (PI3K)-AKT signalling 45 (FIG. 2c) . In addition, another study showed that the amount of collagen VI in the basement membrane regulates fibronectin assembly by restraining cell-fibronectin interactions, which influences HIEC cell migration via the activation of myosin light chain kinases (MLCKs) 46 (FIG. 2d) . However, further in vivo or ex vivo studies are required to understand whether these phenomena occur only in the crypt area, where the LGR5-expressing intestinal stem cells are localized or in other more differentiated areas of the intestine.
How metalloproteinases are involved in ECM remodelling during intestinal development in vertebrates has not been well studied. Although meprin-α and meprin-β are differentially expressed during small intestine development in rats 47 , it is not clear how this affects ECM organizatio n during this process.
So, there is evidence showing that ECM remodelling is essential for intestinal development and maturation; however, our understanding of the molecular mechanisms involved is very limited and thus calls for further studies. Recent advances in ex vivo culture systems, such as the development of intestinal organoids 48 , will allow us to further study the ECM dynamics that govern intestinal development and differentiation. Characterizing ECM components and their role in the adult intestinal stem cell niche will also have implications in understandin g stem cell self-renewal mechanisms.
ECM remodelling in branching morphogenesis
Many organs, including the lungs and the mammary and submandibular glands, are formed during embryonic development by epithelial branching, which establishes the architecture of these organs. Branching involves repetitive formation of epithelial clefts and buds that invade surrounding embryonic ECM, which changes in composition and distribution over time. Although they share some common structural features, each organ is characterized by a specific structure and uses distinct molecular mechanisms for branching (reviewed in REF. 49 ). ECM remodelling plays a crucial part in governing organ branching by providing structural integrity and regulating diverse cellular processes such as cell shape, cell motility and cell growth.
Deposition of ECM proteins controls morphogenesis.
Many ECM components are locally synthesized and reorganized to modulate cell behaviour and promote branching morphogenesis. For example, collagen I and III accumulate at the cleft points of the branching submandibular glands, and treatment with collagenase completely inhibits cleft formation and branching 50, 51 . In mammary glands, collagen I is predominantly localized around the duct 52 , and collagen I fibres are oriented before branching initiation. Collagen I fibres direct epithelial branching by promoting an intracellular reorganization of epithelial cell actomyosin network. This process is mediated by the activation of the RHOA-ROCK pathwa y, which triggers cell contraction 53 (FIG. 3Aa) .
Fibronectin is also essential for cleft formation during the initiation of epithelial branching in the submandibular gland 54 . The local accumulation of fibronectin rapidly induces the expression of the transcriptional regulator BTBD7, which in turn induces local expression of the epithelial-mesenchymal transition (EMT)-promoting factor SNAIL2 and suppresses E-cadherin levels, thus altering cell morphology and reducing cellcell adhesion to promote cleft progression 55 (FIG. 3Ab) .
This cascade is mediated by integrins, which, through the action of focal adhesion kinase (FAK), activate RHOA-ROCK-mediated actomyosin contraction to stabilize the newly formed cleft 56, 57 . RHOA-ROCK inhibit the myosin phosphatase MYPT1 (also known as PPP1R12A), stimulating the phosphorylation of the myosin regulatory light chain (MLC), tipping the balance towards contractility and enhancing α5β1 integrin expression on the cell surface. This modulates fibronectin assembly involved in cell migration and branching morphogenesis in submandibular glands 58 . It will be interesting to investigate whether these signalling events also happen in other branching organs such as mammary glands, in which fibronectin levels are increased during development 59 . Finally, elastin is the most abundant ECM protein in the lungs, and its deposition and remodelling at the leading edge of a growing secondary alveolar septal ridge is crucial for the formation of alveoli in mice 60 . The molecular mechanisms of how elastin deposition controls lung morphogenesis have not been investigated. However, it has been proposed that elastin and collagen deposition increases ECM stiffness in the neonatal lung by facilitating signalling through the endothelial lipoprotein receptor-related protein 5 (LRP5)-TIE2 (also known as angiopoietin 1 receptor) pathway, which is required for normal lung development.[Au: OK?] Indeed, inhibition of collagen III and elastin expression through treatment with β-aminopropionitrile (which inhibits the collagen crosslinking enzyme lysyl oxidase (LOX)) results in softening of neonatal mouse lung tissue and downregulation of the expression of LRP5 and TIE2, which leads to inhibition of the vascular and alveolar morphogenesis in neonatal mice 61 (FIG. 3B) .
Taken together, these results demonstrate that local deposition of specific ECM proteins is crucial for branching organs, not only by giving a structural stability to guide tissue expansion in a certain direction but also by inducing signalling pathways to change cell shape and migration and favouring other events such as vascular ization, which are important for a normal organ development.
ECM cleavage facilitates branching morphogenesis. The ECM at the end bud tip is much thinner than in cleft region and around ducts 62 , suggesting a need to cleave the ECM at the invasive front of the epithelium, giving the cells an opportunity to proliferate, migrate and invade the surrounding mesochyme (FIG. 3A) . The importance of ECM cleavage in this process is evident from the phenotype of mice lacking metalloproteinases: a lack of MMP11 leads to a decreased periductal collagen content and decreased mammary gland morphogenesis 63 . MMP14 is highly expressed at the invading edges of terminal end buds, and its expression increases during branching, indicating that it has a role in the branching process 64 . MMP3 and MMP2 are also involved mammary gland branching morphogenesis: Mmp2-null mice have defects in primary branching, and mice lacking Mmp3 have a defect in side branching but not in primary branching 65 (FIG. 3A) .
In addition to their proteolytic actions, recent studies show that several MMPs, such as MMP3 (REFS 66, 67) and MMP14 (REF. 64 ), regulate invasion and branching in the mammary gland independently of their proteolytic activity. For example, MMP3 uses its haemopexin domain to bind WNT5B and increase the number of mammary stem cells and branching morphogenesis 66 , whereas MMP14 uses its transmembrane and cytoplasmic domains to regulate the expression and activity of β1 integrin to control cell invasion and mammary gland branching. These data show that MMPs function both proteolytically and non-proteolytically to regulate the extracellular m icroenvironment during branching morphogenesis.
ECM remodelling releases growth factors. The ECM functions as a ligand 'reservoir' by binding numerous growth factors. In this way, ECM can retain some growth factors that can be proteolytically released and can locally induce proliferation and branching morphogenesis The affinity of FGFs for HSPGs varies and regulates their gradient and effects on submandibular gland branching. As FGF10 binds HSPGs with high affinity, only a portion of the epithelium is exposed to this growth factor, resulting in directional outgrowth of elongating ducts in submandibular glands. By contrast, FGF7 binds HSPG with low affinity, and its gradient is broader, inducing the formation of many buds in multiple directions 69 (FIG. 3Ca) . In addition, heparanase endogenously colocalizes with perlecan in the basement membrane and in submandibular gland cleft. The addition of heparanase Aa | Collagen is locally synthesized and aligned to increase extracellular matrix (ECM) stiffness and create a mechanical anisotropy that will drive branching. Collagen synthesis is mediated by the activation of the RHOA-RHO-associated protein kinase (ROCK) signalling pathway. The ECM at the end bud tip is much thinner than in cleft region and around the duct. Matrix metalloproteinase 2 (MMP2) and MMP14 are expressed and active at the end bud tip, whereas MMP3 is involved in side branching. Ab | Cleft formation and deepening in the submandibular glands. Fibronectin is locally assembled in the basement membrane and induces BTBD7 at the base of forming clefts, which in turn upregulates the transcription factor SNAIL2 and downregulates the adhesion molecule E-cadherin. These molecular events promote alterations in cell shape, decreasing cell-cell adhesion and promoting a motile phenotype to promote cleft progression. Fibronectin assembly requires focal adhesion kinase (FAK) activation and RHOA-ROCK-mediated actomyosin contraction. B | Role of elastin and collagen deposition in alveolar branching in the lung. Elastin and collagen deposition promotes ECM stiffness in the neonatal lung and facilitates signalling through the endothelial lipoprotein receptor-related protein 5 (LRP5)-TIE2 (also known as angiopoietin 1 receptor) pathway, which is required for normal lung development. Consistent with this, disrupting lung collagen I, III and VI and elastin expression and localization through treatment with β-aminopropionitrile, an inhibitor of the collagen crosslinking enzyme lysyl oxidase (LOX), softens neonatal mouse lung tissue and downregulates the expression of LRP5 and TIE2, which leads to an inhibition of vascular and alveolar morphogenesis in neonatal mice. Ca | Heparan sulphate proteoglycans (HSPGs) bind fibroblast growth factors (FGFs) with different affinity and help to create a concentration gradient that can control cell fate in submandibular glands. In contrast to FGF10, FGF7 binds HSPG with low affinity and diffuses broadly, promoting branching in the submandibular gland. Cb | HSPGs such as perlecan bind FGF10 with high affinity. Following cleavage by heparanase, perlecan releases FGF10, which can then diffuse locally and promote duct elongation. FGFR2, FGF receptor 2; MLC, myocin light chain; MYPT, myosin phosphatase. to submandibular gland cultures increases morphogenesis owing to the release of FGF10 from perlecan and the activation of mitogen-activated protein kinase (MAPK) signalling 69, 70 (FIG. 3Cb) These data show that ECM remodelling through proteolytic degradation can release growth factors from the ECM reservoir, which can affect epithelial cell proliferation and migration and regulate organ morphogenesis.
Aberrant ECM remodelling in disease
Given the crucial importance of the ECM during develop ment and for the maintenance of tissue homeostasis, it is not surprising that dysregulation of ECM components can lead to disease. For example, mutations in genes that encode factors that affect the composition and architecture of the ECM, such as COL1A1 (α-chain of collagen I), result in severe defects in bone formation. However, aberrant ECM remodelling can also lead to various pathological states in more subtle ways such as in osteoarthritis, fibrosis and cancer.
Increased ECM breakdown causes tissue destruction. The importance of ECM homeostasis is clear from diseases characterized by abnormal ECM breakdown, a process primarily mediated by proteinases such as MMPs and ADAMs. For example, abnormally high levels of heartspecific MMP1 expression result in collagen loss and diminished contractility that leads to cardiomyopathy 71 . In osteoarthritis, ADAMTS4 and ADAMTS5 are abnormally overexpressed and are partially responsible for the pathological destruction of cartilage ECM 72 . The mechanisms mediating metalloproteinase upregulation remain unclear but may involve receptors involved in cell-ECM interactions, such as syndecan 4, which activate MMP3 and ADAMTS5 to promote ECM breakdown 73 (FIG. 4A) . Interestingly, loss-of-function mutations in MMP2 also cause a severe osteolytic and arthritic syndrome 74 . This counterintuitive discovery that deficiency of a protease results in osteolysis and arthritis demonstrates that normal bone and cartilage homeostasis depends on balanced ECM breakdown and synthesis. Taken together, these studies highlight the importance of an intact ECM network in maintaining tissue architecture, support and homeostasis.
Excess ECM leads to pathological fibrosis. Chronic or severe tissue injuries leading to excessive ECM production and deposition without reciprocally balanced degradation can result in fibrosis (FIG. 4B) . This aberrant healing process can be so severe that it leads to organ failure, such as cirrhosis in the liver or myelofibrosis in the bone marrow. Fibrosis also increases the risk of cancer; for example, liver cirrhosis increases the risk of hepatocellular carcinoma by 20-30% 75 , and increased mammographic density, which reflects the amount of collagen in the breast, correlates with increased risk of breast cancer 76 . Fibrosis is mediated primarily by fibroblasts or myofibroblasts, as well as other stromal cells. The TGFβ pathway is perhaps the most well-studied and potent stimulator of fibrosis 77 . TGFβ induces the translocation of the SMAD2-SMAD3 complex of transcription factors into the nucleus, where it directly promotes the expression of ECM genes such as COL1A1, COL3A1 and TIMP1, as well as about 60 other ECM-related genes 78 . Owing to space limitations, the reader is referred to several excellent recent reviews regarding additional molecular signals that regulate fibrosis [79] [80] [81] . Some cytokines, such as interleukin-33 (IL-33), promote fibrosis by activating immune cells 82 . In the liver, IL-33 promotes the expansion of resident innate lymphoid cells, which produce IL-13 to activate hepatic stellate cells, the main ECM producers in the liver. IL-13 promotes fibrosis by stimulating collagen accumulation, downregulating MMPs and recruiting profibrotic innate immune cells 83 . IL-13 also promotes the differentiation of fibroblasts into myofibroblasts and increases TGFβ expression 84 . How these cytokines and growth factors are upregulated in different tissues remains to be elucidated. In the case of the intestinal tract, recent studies have suggested that the microbiome is an important pro-inflammatory component that stimulates fibrosis 85 . Interestingly, it was recently shown that a fibrotic ECM can stimulate fibroblasts to further increase ECM production 86 . Experiments in which ECM and fibroblasts were isolated from patients with or without idiopathic pulmonary fibrosis (IPF) and then co-cultured indicated that the origin of the ECM had a greater effect on gene expression than the origin of the fibroblasts. ECM derived from patients with IPF increased ECM production in both non-IPF and IPF fibroblasts by inducing downregulation of the microRNA miR-29, which regulates the expression of many ECM gene products 86 . In addition, fibronectin extra domain A (EDA) fragments, which are increased in patients with sclero derma, stimulate collagen production via Toll-like receptor 4 (TLR4) signalling and induce myofibroblast differentiation and ECM stiffness. This ultimately leads to chronic cutaneous fibrosis 87 . Taken together, these studies demonstrate that the ECM actively participates in stimulating further ECM synthesis. These ECMdriven pathways that further exacerbate fibrosis may be amenable to therapeutic intervention
Mechanisms that limit fibrosis. Signalling mediators such as interferon-γ (IFNγ) and peroxisome proliferatoractivate d receptor-γ (PPARγ) exert their anti-fibrotic effects by antagonizing TGFβ signalling. Vitamin D receptor (VDR) ligands, for example, decrease liver fibrosis by redirecting VDR to SMAD3 sites on the DNA, thereby reducing SMAD3 occupancy. This molecular competition for binding sites inhibits SMAD3-mediated transcription of ECM targets and prevents hepatic stellat e cell activation in the liver 88 .
In addition, MMPs have also been shown to be antifibrotic in specific tissue microenvironments 80 . For example, MMP12 limits fibrosis during corneal injury by altering the expression of CC-chemokine ligand 2 (CCL2) and CXC-chemokine ligand 1 (CXCL1) and therefore interfering with the infiltration of immune cells 89 . Similarly, the transmembrane HSPG syndecan 4 , results in osteoarthritis and increased breakdown of the connective tissue. B | As a result of chronic inflammation or tissue injury, transforming growth factor-β (TGFβ), connective tissue growth factor (CTGF), interleukin-13 (IL-13) and other factors stimulate fibroblasts and myofibroblasts (the main ECM producers) to produce more ECM, resulting in pathological fibrosis. The excess ECM further stimulates fibroblasts to continue making ECM, forming a positive feedback loop. Fibrosis is a major risk factor for developing cancer, including hepatocellular carcinoma and breast cancer. C | The ECM contributes to cancer pathogenesis by several mechanisms: functioning as a barrier to chemotherapy, to monoclonal antibodies such as cetuximab and to immune therapy mediated, for example, by cytotoxic T cells (CTLs) (part Ca); forming migration track 'highways' that regulate the interaction of immune cells with cancer cells (part Cb); stimulating integrin signalling through increased ECM stiffness, which promotes ECM synthesis, invasion and proliferation (lysyl oxidase (LOX) and LOX-like 2 (LOXL2) are enzymes that crosslink collagen and are the main enzymes responsible for increasing ECM stiffness) (part Cc); forming a niche for new metastatic cells and providing survival and proliferative signals (part Cd); generating novel bioactive ECM fragments from native ECM chains, and stimulating cell migration or immune cell recruitment (part Ce); activating cell-ECM receptors such as discoidin domain-containing receptor 1 (DDR1) and DDR2, which bind directly to collagen and regulate transcriptional pathways to increase MMP and epithelial-mesenchymal transition (EMT) marker expression (part Cf); and sequestering growth factors that can be released by proteolytic cleavage, which then diffuse to bind receptors to stimulate cell growth, EMT or angiogenesis (part Cg).
inhibits fibrosis by binding the chemokine CXCL10 and preventing fibroblast migration to areas of injury, so that new ECM cannot be deposited at these sites 90 . Of note, recent studies highlight the importance of divergent chemokine signals in the liver that control the balance between fibrosis and tissue repair 91 . Perturbing chemokine expression and gradients (such that different cell types with varying propensities to deposit ECM are recruited) is an important way to indirectly affect the local ECM.
Interestingly, other mechanisms besides proteasemediated degradation of the ECM can also limit fibrosis. One such mechanism is cellular re-uptake of ECM proteins. For example, milk fat globule EGF 8 (MFGE8; also known as lactadherin) inhibits pulmonary fibrosis by binding collagen and promoting its uptake by macrophages 92 ; collagen can then be degraded by lysosomal pathways. This illustrates an important alternative process to facilitate the removal of collagen from the extracellular space. Additional receptors that promote endocytosismediated degradation of other ECM components and the basis for the specific uptake of individual components will be important to identify and may yield new strategies for attenuating fibrosis.
ECM stiffness and remodelling in cancer progression.
The ECM provides essential signals to maintain tissue architecture and polarity and to regulate cell growth and apoptosis. In the appropriate context, the ECM is sufficient to restrain malignant tumour progression 93 . For example, a high molecular mass hyaluronan (that is, more than five times larger than human or mouse hyaluronan) protects against cancer in naked mole rats 94 . HA accumulates abundantly in naked mole-rat tissues owing to the decreased activity of HA-degrading enzymes and a unique sequence of hyaluronan synthase 2 (HAS2).
However, the ECM can also promote tumour progression (reviewed in REFS 1, 6, 95) . For example, collagen IV overexpression enhances cell survival and provides a growth advantage for lung cancer cells in the liver 96 . In fact, ECM gene signatures can stratify breast cancer into subclasses that predict patient outcome. Tumours with high expression of protease inhibitors correlate with good prognosis, whereas those with high MMPs correlate with poor prognosis and increased risk of recurrence 97 . In addition, high MMP1 expression stratifies atypical ductal hyperplasia into benign versus pre-malignant lesions that are at risk for becoming cancer 98 . Several recent studies also point to the importance of the ECM in facilitating metastatic tumour cell growth in the metastatic niche
Insights into ECM elasticity and stiffness, which is determined by ECM organization, orientation and chemical modification, have challenged our understanding of how cells interact with, and respond to, the microenvironment. For example, ECM stiffening, induced by increased collagen deposition and crosslinking, disrupts tissue morphogenesis and contributes to malignant progression 99 . Collagen crosslinking is mediated primarily by LOX and LOX-like (LOXLs) enzymes, which are frequently overexpressed in many cancers and at metastatic sites, and patients with high LOX expression have poor survival 100 . In breast cancer, LOX-induced collagen crosslinking increases stiffness, β1 integrin clustering, PI3K signalling and focal adhesion formation to drive invasion and tumour progression (FIG. 4C) . Conversely, inhibiting LOX suppresses fibrosis and increases tumour latency 101 . ECM stiffening also facilitates metastatic colonization and infiltration of tumour-promoting immune cells 102 , and induces the expression of miR-18a, which is pro-tumorigeni c by targeting the tumour suppressor phosphatase and tensin homologue (PTEN) 103 .
Box 2 | Extracellular matrix remodelling as a potential therapeutic target
Targeting the extracellular matrix (ECM), the enzymes that remodel it and the receptors that transduce their signals offers promising therapeutic opportunities for many diseases. For example, one study found that injecting ECM scaffolds derived from decellularized porcine myocardial tissue into porcine models of myocardial infarction can improve cardiac function 137 . These ECM scaffolds seemed to be haemocompatible and to not induce a pathological pro-inflammatory reaction. Although the number of pigs tested in this study was small, the findings support advancing this strategy into human trials. Other ECM molecules such as perlecan have been shown to be neuroprotective after acute stroke by promoting the secretion of vascular endothelial growth factor (VEGF) and angiogenesis, which ultimately promotes motor function recovery in rodent models 138 . In addition, strategies to increase growth factor affinity to the ECM (via a domain derived from placental growth factor 2 (PlGF2)) may improve repair of chronic wounds and bone defects 139 , but these studies are still in the preclinical stages.
However, some ECM proteins compromise wound repair and regeneration. For example, chondroitin sulphate proteoglycans (CSPGs) generated after trauma or spinal cord injury inhibit neuronal repair 140, 141 . Treatment with chondroitinase ABC enzymes improves nerve regeneration in mouse models 142 . In addition, hyaluronan, which accumulates in patients with multiple sclerosis, prevents remyelination and inhibits oligodendrocyte maturation. Consistent with this, degrading hyaluronan promotes oligodendrocyte maturation in vitro, which may improve nerve regrowth 143 . Therefore, therapeutics that degrade the abnormal ECM may be beneficial in these conditions.
Strategies to target the enzymes involved in remodelling the ECM are also being pursued. For example, inhibiting lysyl oxidase-like 2 (LOXL2) using the antibody simtuzumab showed promising results in mouse models of fibrosis 144 . Simtuzumab is currently being evaluated in Phase 2 and Phase 3 clinical trials for scleroderma, idiopathic pulmonary fibrosis (IPF) and cancer. Matrix metalloproteinase (MMP) inhibitors (such as marimastat and prinomastat), which were initially thought to be promising anticancer agents, have unfortunately not demonstrated efficacy in the clinic. This is due to their lack of specificity and also their poor tolerability 145 . Therefore, altering individual MMPs using monoclonal antibodies may be more promising 146 . In addition, MMPs have non-proteolytic functions and so inhibiting these other domains (for example, the haemopexin domain) needs to be considered, as well as the timing of MMP inhibitor administration as MMPs can have opposing functions at different stages of disease 147 . Furthermore, given the importance of transforming growth factor-β (TGFβ) in regulating ECM gene expression, several trials are currently evaluating a TGFβ-inhibitory antibody, fresolimumab, in systemic sclerosis, IPF and myelofibrosis.
ECM stiffness can influence responses to anticancer agents by regulating access to chemotherapy 148 and potentially forming a physical barrier to promote resistance 149 (FIG. 4c) . In addition, lung cancer cells that express high levels of fibronectin, laminin and collagen IV are protected against chemotherapy-induced apoptosis 150 . Notably, recent work has shown that the epidermal growth factor receptor (EGFR) inhibitor cetuximab actually self-attenuates its cytotoxic effects by inducing the synthesis of fibronectin and promoting radioresistance 151 . Therefore, targeting the ECM may be an important strategy to improve tumour responses to systemic and radiation therapy.
Finally, several drugs targeting integrins, including natalizumab (which targets α4 integrin) for multiple sclerosis and Crohn's disease and abciximab (which targets glycoprotein IIbx-IIIa) for thrombotic disorders, are being investigated. Targeting α5 integrin may also be promising for various fibrotic diseases 152 . Further work is clearly required to translate preclinical studies to the clinic. However, taken together, these studies illustrate several exciting advances in perturbing the ECM to treat several human diseases. Collagen also signals to cells through the receptor Tyr kinases discoidin domain-containing receptor 1 (DDR1) and DDR2, both of which have been implicated in cance r (reviewed in REF. 104) (FIG. 4C) . DDR1 is required for collective cell migration 105 , and increased expression of DDR2 has been observed in invasive human breast tumours 106 . Notably, DDR2 activation stabilizes the transcription factor SNAIL1, which induces collagen I and MMP14, and promotes EMT and metastasis 106 . The extracellular collagen network can therefore alter cellintrinsic properties such as epithelial plasticity through these cell receptors. Together, these data demon strate that collagen crosslinking activates signalling pathways and miRNA networks that promote malignant progression.
Several studies have implicated miRNAs as potent regulators of the ECM. The miR-29 family, for example, controls the expression of a network of genes involved in ECM remodelling, including several collagen chains, LOX and LOXLs, as well as MMP2 and MMP9 (REFS 107, 108) . In breast cancer, miR-29 expression inversely correlates with cell adhesion and ECM gene expression 109 , and miR-29b overexpression alters the tumour microenviron ment and suppresses metastasis 108 . Additional studies are required to identify other miRNAs that are important in regulating the ECM and to determine whether other non-coding RNAs, such as long non-coding RNAs, might also regulate the chromatin state, and therefore transcription, of ECM genes. Factors upstream of these non-coding RNAs will also be important to identify. This exciting area of biolog y should yield additional insights into how ECM remodellin g is controlled.
The ECM promotes angiogenesis. The ECM also modulates angiogenesis to promote tumour growth 110 . For example, in a pancreatic β-cell tumour model, tenasci n C not only promotes tumour cell survival and prolifer ation but also induces angiogenesis and blood vessel permeability by downregulating Dickkopf 1 (DKK1) and increasing WNT signalling 111 . In addition, ECM fragments generated by cleavage of the full-length ECM protein also have pro-and antiangiogeni c functions. These include endostatin, tumstatin, canstatin, arresten and hexastatin, all of which are derived from collagen IV and XVIII (reviewed in REF. 112) and can bind to cell receptors such as integrins and EGFR 113 . For example, arresten, which is generated from the NC1 domain of the collagen α1(IV) chain, binds to α1β1 integrin and inhibits angiogenesis by antagonizing MAPK signalling 114 . Together, these studies demonstrate that the ECM also promotes non-cell autonomous mechanisms to enhance tumour growth (FIG. 4C) .
The ECM regulates immune and cancer cell migration.
Immune responses occur in the context of integrinmediate d adhesive interactions with the ECM. For example, α1β1 integrin, which binds collagen I and IV, is expressed by peripheral CD8 + T cells during influenza infection and mediates retention of influenza-specific memory T cells in the lung after viral clearance, which is important for secondary immunity 115 . Furthermore, the ECM niche within the spleen, which consists of laminin and agrin, promotes marginal zone B cell differentiation and survival to support antibody production 116 . These studies highlight the importance of the ECM in mediatin g immune responses.
Many ECM proteins also contain cryptic domains with structures that are similar to chemokines and cytokines 117 . These domains can be exposed by proteolysis and elicit biological responses that are distinct from those of the full length ECM component (FIG. 4C) . These matrikines regulate many processes, including Box 3 | The extracellular matrix is a crucial component of the metastatic niche Successful metastasis requires not only a local niche to support primary tumour growth but also a metastatic niche to enable disseminated cancer cells to survive, colonize and proliferate at a distant site 153 . This niche consists of various extracellular matrix (ECM) components and the enzymes that remodel them (for example, matrix metalloproteinases (MMPs)), as well as other cell types such as bone marrow-derived cells (BMDCs), endothelial cells and fibroblasts. For example, before the arrival of tumour cells, Lewis lung carcinoma (LLC) cells upregulate fibronectin at sites of future metastasis, which promotes BMDC clustering through α4β1 integrin 154 . These BMDCs are recruited to the metastatic site by tumour-derived factors and express MMP9 to facilitate breakdown of the basement membrane. Thus, ECM remodelling occurs as an early step in metastasis to help circulating tumour cells colonize and thrive in distant organs.
In addition to fibronectin, other ECM components support the metastatic niche. Tenascin C, which is normally enriched in stem cell niches, is initially expressed by breast cancer cells and later by stromal cells to promote survival and outgrowth of lung metastases 155 . Periostin, another ECM component that is important in bone and tooth development, promotes metastatic colonization by recruiting WNT ligands, thereby increasing WNT signalling in cancer stem cells 156 . Periostin expression by fibroblasts is induced by infiltrating tumour cells via transforming growth factor-β (TGFβ), and is required for cancer stem cell maintenance. Interestingly, endothelial tip cells within new vascular sprouts secrete both periostin and TGFβ, which promotes angiogenesis and micrometastatic outgrowth 157 . Furthermore, LLC-conditioned medium contains versican, which is a large chondroitin sulphate proteoglycan that is upregulated by many human tumours. Versican activates macrophages through Toll-like receptor 2 (TLR2) to produce interleukin-6 (IL-6) and tumour necrosis factor (TNF), thereby establishing a pro-inflammatory microenvironment that is conducive for metastatic growth 123 . Osteopontin in gliomas also promotes stem cell-like properties and radioresistance via CD44 signalling 158 .
A systematic approach to identify responses to ECM has further uncovered ECM molecules that promote metastasis 159 . Taken together, these studies illustrate how the ECM regulates metastasis and suggest that inhibiting the ECM niche may be therapeutically beneficial in cancer.
migration, adhesion and differentiation, and can affect immune and pro-inflammator y cell behaviour 118 . For example, N-acetyl Pro-Gly-Pro (PGP) is a bioactive collagen I fragment generated by MMP8 and MMP9. PGP shares structural homology with CXC chemokines and signals through CXC-chemokine receptor 1 (CXCR1) and CXCR2 to attract neutrophils to sites of inflammation 119 . Interestingly, these PGP collagen derivatives are found in patients with chronic inflammatory airway disorders, which illustrates their relevance in human d isease 120 . Other ECM fragments, such those generated by overexpressing hyaluronidase 1, promote dendritic cell egress from the skin to facilitate antigen presentation. This migration is mediated by TLR4, as mice lacking this receptor do not exhibit hyaluronan-associated phenotypes 121 . These studies demonstrate the importance of ECM fragments in controlling immune cell migration, which may be exploited therapeutically to treat pro-inflammatory diseases.
The density and orientation of the ECM fibres also controls immune cell migration. Loose areas of fibronectin and collagen facilitate T cell motility, whereas dense ECM areas impede migration. These ECM fibres also govern cell migratory tracks, which can restrict the inter action of immune cells with cancer cells 122 (FIG. 4C) . Notably, treatment with collagenase enhances the contact of T cells with cancer cells, suggesting that modulating ECM architecture might be an important way to improve immunotherapy access. Other ECM components, such as versican, recruit and activate protumorigen ic immune cells such as macrophages, thereby promoting inflammatio n and metastasis 123 . Interestingly, ECM geometry dictates the mode of cell migration, as cells can use both proteolytic and non-proteolyti c mechanisms to migrate and squeeze through the ECM 124 . Confined ECM geometries alter cell deformability and shift the relationship between adhesion, contractility and velocity to promote bleb migration patterns at tumour margins 125 . Together, these studies illustrate how the ECM regulates immune and cancer cell migration.
Abnormal release of growth factors during pathogenesis.
The ECM is a rich reservoir of growth factors and other bioactive molecules that can be released by proteolysis via MMPs (FIG. 4C) . For example, in pancreatic neuroendocrine tumours, VEGF is abundant in the ECM, even in non-angiogenic islets. The switch from vascular quiescence to active angiogenesis involves upregulation of MMP9, which releases sequestered VEGF from the ECM 126 . In addition to MMPs 127 , the Ser protease plasmin can also release ECM-bound VEGF into soluble forms 128 . The multiple isoforms of VEGF generated by alternative splicing have unique C-terminal domains, which allow some isoforms to bind collagen and fibrinogen 129 . In addition, HSPGs interact with platelet-derived growth factor (PDGF) in a sulphation-dependent manner. Inhibition of sulphatase 2 decreases growth in glioblastomas by attenuating PDGF receptor signalling, indicating that the ECM and the enzymes that modify it control the bioavailability of growth factors 130 .
TGFβ is also sequestered and bound to PGs in the ECM. In osteogenesis imperfecta, impaired collagen formation leads to reduced binding to decorin, a known regulator of TGFβ activity, which results in over-active TGFβ signalling 131 . Excessive TGFβ signalling is a common driving mechanism in many mouse models of osteogenesis imperfecta, and treatment with TGFβ-specific antibodies partially corrects the bone phenotype in mice. In addition, the fibrinogen-like domain of tenascin X interacts with the small latent TGFβ complex and regulates the bioavailability of mature TGFβ, which controls EMT in mammary epithelial cells 132 . These studies establish a role for the ECM as an important reservoir of growth factors and as an indirect regulator of signal transduction in multiple diseases.
Summary and conclusions
The ECM is a vital structure that has a dynamic and complex organization and can trigger multiple biological activities that are essential for a normal organ development and tissue homeostasis. Dysregulated ECM remodelling leads to many diseases, including fibrosis and cancer.
In this Review, we describe how ECM remodelling affects organ morphogenesis, using the intestine, the lung, and the mammary and submandibular glands as examples. In all four cases, appropriate development requires the tight control and regulation of ECM assembly, modification and degradation. However, unique mechanisms must be at play for each organ, given their distinct structure and function. The exact nature of these organ-specific mechanisms remains elusive. Is the molecular mechanism involved in submandibular gland cleft formation (which involves deposition of fibronectin at the cleft site driven by BTBD7) specific to this organ, or is it generalizable to other branched organs? What is the role of the microenvironment, which includes immune cells, endothelial cells and fibroblasts, in ECM remodelling, and how does this influence the branched pattern of each organ? It will be interesting to investigate the interactions between the ECM, epithelial cells and microenvironment in organogenesis.
In addition, the role of the ECM in regulating the stem cell niche needs to be more extensively explored. For example, a single mammary stem cell can reproduce an entire organ when transplanted into a cleared fat pad. This suggests the presence of a niche in the mammary gland that contains all the signals required to programme stem cells. The ECM has a crucial role in the release of the niche signals that are essential for stem cell fate 133 , which probably has implication for diseases such as cancer, in which cancer stem cells might also be using such ECM signals to promote their survival and growth. A better understanding of the niche signals that regulate stem cell behaviour might also have therapeutic potential in regenerative medicine.
Ex vivo three-dimensional organoids cultured in Matrigel has improved our understanding of the development of branching organs. However, these models do not recapitulate the complex microenvironment of the developing organ, nor do they reproduce the exact compositio n and stiffness of the native ECM. Organotypic tissue culture systems that incorporate native ECM and stromal cells will continue to improve our understanding of cancer 134 and enable us to study developmental and disease processes in more physiologic environments that better model human disease 135 . The identification of the matrisome and key ECM remodelling effects that promote certain diseases opens several exciting possibilities for therapeutic intervention. Attention must be given to targeting specific individual ECM components as well as to timing the therapy correctly, given that the ECM is actively remodelled. Current clinical trials using inhibitors of ECM-related targets are ongoing and promising
. However, a deeper understanding of the diverse biologic activities and properties of the ECM must be attained to uncover new targets for future therapy.
